Clinical Trials Browser

Prostatic Neoplasms

NCT06120491 2026-05-27

EvoPAR-PR01

Phase 3 Active not recruiting

1,889 enrolled

Genitourinary

Prostatic Neoplasms

NCT03582774 2026-05-26

PSMA SRT

Phase 3 Active not recruiting

193 enrolled

Genitourinary

Prostatic Neoplasms

NCT02799706 2026-05-22

PEGASUS

Phase 3 Active not recruiting

885 enrolled

Genitourinary

Prostatic Neoplasms

NCT03987386 2026-05-20

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3 Active not recruiting

186 enrolled

Genitourinary

Prostatic Neoplasms

NCT07477626 2026-05-19

RADVAN

Phase 3 Active not recruiting

372 enrolled

Genitourinary

Prostatic Neoplasms

NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Phase 3 Active not recruiting

707 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03574571 2026-05-14

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Phase 3 Active not recruiting

732 enrolled

Genitourinary

Prostatic Neoplasms

NCT06970847 2026-05-14

AMPLIFY

Phase 3 Active not recruiting

220 enrolled

Genitourinary

Prostatic Neoplasms

NCT01946204 2026-05-11

SPARTAN

Phase 3 Active not recruiting

1,207 enrolled 15 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT02257736 2026-05-11

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT02489318 2026-05-11

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT01368588 2026-05-08

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3 Active not recruiting

2,590 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT02531516 2026-05-08

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

1,503 enrolled

Genitourinary

Prostatic Neoplasms

NCT03767244 2026-05-08

PROTEUS

Phase 3 Active not recruiting

2,517 enrolled

Genitourinary

Prostatic Neoplasms

NCT04557059 2026-05-08

PRIMORDIUM

Phase 3 Active not recruiting

692 enrolled

Genitourinary

Prostatic Neoplasms

NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Phase 3 Active not recruiting

1,068 enrolled 20 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT02446444 2026-05-06

ENZARAD

Phase 3 Active not recruiting

802 enrolled

Genitourinary

Prostatic Neoplasms

NCT04136353 2026-05-06

DASL-HiCaP

Phase 3 Active not recruiting

1,100 enrolled

Genitourinary

Prostatic Neoplasms

NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Phase 3 Active not recruiting

27 enrolled

Genitourinary

Prostatic Neoplasms

NCT04493853 2026-05-05

CAPItello-281

Phase 3 Active not recruiting

1,012 enrolled

Genitourinary

Prostatic Neoplasms

NCT06551324 2026-05-05

MEVPRO-1

Phase 3 Active not recruiting

600 enrolled

Genitourinary

Prostatic Neoplasms, Recurrence

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

2,753 enrolled

Genitourinary

Prostatic Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

599 enrolled

Genitourinary

Prostatic Neoplasms

NCT05678322 2026-03-25

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

Phase 3 Active not recruiting

26 enrolled 7 charts

Genitourinary

Prostatic Neoplasms

NCT04689828 2026-03-23

PSMAfore

Phase 3 Active not recruiting

469 enrolled 11 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT05154162 2026-03-03

PRIMARY2

Phase 3 Active not recruiting

660 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT04455750 2026-02-05

CASPAR

Phase 3 Active not recruiting

61 enrolled

Genitourinary

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

Phase 3 Active not recruiting

455 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

1,380 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT02194842 2025-09-19

PEACE III

Phase 3 Active not recruiting

446 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01230866 2025-09-04

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

Phase 3 Active not recruiting

150 enrolled

Genitourinary

Prostatic Neoplasms

NCT05336786 2025-09-04

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Phase 3 Active not recruiting

70 enrolled

Genitourinary

Prostatic Neoplasms

NCT01407263 2025-08-14

Trial of Modifications to Radical Prostatectomy

Phase 3 Active not recruiting

3,204 enrolled

Genitourinary

Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

439 enrolled

Genitourinary

Prostatic Neoplasms

NCT01436968 2025-07-30

PrTK03

Phase 3 Active not recruiting

711 enrolled

Genitourinary

Prostatic Neoplasms

NCT04181203 2025-07-30

CARLHA-2

Phase 3 Active not recruiting

490 enrolled

Genitourinary

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Phase 3 Active not recruiting

925 enrolled 12 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT03531099 2025-06-22

HIFUSA

Phase 3 Active not recruiting

108 enrolled

Genitourinary

Prostatic Neoplasms

NCT02804815 2025-06-10

Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

Phase 3 Active not recruiting

11,000 enrolled

BreastGastrointestinalGenitourinary

Breast Neoplasms, Neoplasms, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Phase 3 Active not recruiting

1,792 enrolled 27 charts

Genitourinary

Prostatic Neoplasms

NCT04302454 2025-04-04

ADOPT

Phase 3 Active not recruiting

280 enrolled

Genitourinary

Prostatic Neoplasms

NCT02692105 2025-03-13

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

Phase 3 Active not recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT04557501 2025-03-13

PATRON

Phase 3 Active not recruiting

800 enrolled

Genitourinary

Prostatic Neoplasms

NCT05004285 2025-03-12

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

Phase 3 Active not recruiting

398 enrolled

Genitourinary

Prostatic Neoplasms

NCT05936658 2025-03-12

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

Phase 3 Active not recruiting

138 enrolled

Genitourinary

Prostatic Neoplasms

NCT05676203 2025-02-17

ARASAFE

Phase 3 Active not recruiting

250 enrolled

Genitourinary

Prostatic Neoplasms

NCT02446405 2025-02-06

ENZAMET

Phase 3 Active not recruiting

1,125 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

PSMAddition

EvoPAR-PR01

PSMA SRT

PEGASUS

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

RADVAN

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

AMPLIFY

SPARTAN

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

TITAN

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

PROTEUS

PRIMORDIUM

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

ENZARAD

DASL-HiCaP

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

CAPItello-281

MEVPRO-1

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

PSMAfore

PRIMARY2

CASPAR

SPLASH

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

CONTACT-02

PEACE III

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Trial of Modifications to Radical Prostatectomy

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

PrTK03

CARLHA-2

KEYNOTE-641

CYCLONE 3

HIFUSA

Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

ADOPT

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

PATRON

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

ARASAFE

ENZAMET